A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation

Recruiting

Phase 2

RLY-2608A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation

Sponsor:

Relay Therapeutics, Inc.

Code:

NCT06789913

Conditions

PIK3CA-Related Overgrowth Spectrum (PROS)

Lymphatic Malformations

Vascular Malformations

PIK3CA Mutation

CLOVES Syndrome

Eligibility Criteria

Sex: All

Age: 2+

Healthy Volunteers: Not accepted

Interventions

RLY-2608

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-05-18. This information was provided to ClinicalTrials.gov by Relay Therapeutics, Inc. on 2026-05-05.